Alisertib + Endocrine therapy
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hormone Receptor Positive HER-2 Negative Breast Cancer
Conditions
Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Trial Timeline
Nov 19, 2024 → Dec 31, 2028
NCT ID
NCT06369285About Alisertib + Endocrine therapy
Alisertib + Endocrine therapy is a phase 2 stage product being developed by Puma Biotechnology for Hormone Receptor Positive HER-2 Negative Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06369285. Target conditions include Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06369285 | Phase 2 | Recruiting |
Competing Products
20 competing products in Hormone Receptor Positive HER-2 Negative Breast Cancer